Syndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.
1 report, 1 independent
Updated Jun 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Syndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Syndax Pharmaceuticals
business
Nothing else this week.
- FDA
Related events
- Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- Acurx Pharmaceuticals trades on NASDAQ and is receiving FDA guidance supporting its potential approval pathway.
- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.